Shares of Edenred surged on Thursday following a media report that suggested Britain-based private-equity firm BC Partners has been considering a takeover of the French employee-benefits provider.
In Paris trading the stock climbed more than 16%, changing hands at 24.07 euros by 04:02 ET (08:02 GMT).
According to the report from French newsletter La Lettre A, BC Partners has been studying a potential take-private of Edenred for the past three months and is looking for consortium partners to back a bid. The newsletter said that, as of the report, no formal offer had been submitted to Edenred's management or board.
Market analysts weighed in on how Edenred's financial profile could appeal to private-equity buyers. Research from Kepler Cheuvreux singled out the company’s depressed valuation, recurring revenue streams, strong free cash flow and relatively low leverage, together with the reach of its global platform, as attributes that could make it attractive despite oversight risks in some markets.
Kepler Cheuvreux also noted regulatory exposures specifically in Brazil and Italy and pointed to ongoing antitrust scrutiny as obstacles that could complicate a transaction. The brokerage quantified a potential indicative bid range, saying a EUR27-28 offer would represent roughly a 30-35% premium to recent prices, while still being opportunistic when measured against normalised earnings and the firm’s expected recovery by 2027 as well as upside in average revenue per user (ARPU).
The analysts further commented that such an offer range would underscore what they see as a current market discount in Edenred’s valuation.
This development places Edenred in focus for investors and deal watchers, as the combination of private-equity interest and analyst valuation work can quickly reshape market pricing even before any formal bid is lodged. For now, the situation described in the report remains preliminary: BC Partners is said to be in a review and partner-sourcing phase, and Edenred’s management and board had not received an approach at the time of the article.
Investors will likely monitor any follow-up reporting for confirmation of an approach or statements from the parties involved, while market participants weigh the balance between the company’s cash-generation profile and the regulatory and antitrust challenges highlighted by analysts.